Answers are grounded in this paper and cite their sources.
Cross-sectional study evaluates CD28 expression in T-cells and its relation to disease activity in SLE, suggesting a potential biomarker.
Background CD28, a key T-cell co-stimulatory molecule, is implicated in immune dysregulation in SLE patients and may serve as a biomarker for disease activity. Objectives This research pointed to evaluate relations between CD4 + CD28 + and CD8 + CD28 + T-cell percentages and SLE activity (SLEDAI-2 K), clinical/laboratory markers. Methods This cross-sectional study involved 100 people (34 controls, 66 SLE patients diagnosed according to the 2019 EULAR/ACR criteria for SLE and stratified by SLEDAI-2 K into a group with mild activity [ n = 33] and a group with high activity [ n = 33]). Flow cytometry quantified CD28 expression on CD4 + /CD8 + T-cells. Results High-activity SLE featured more hypertension (36.4% vs 21.2% in low-activity patients), renal issues (proteinuria 66.7%, hematuria 48.5%, casts 42.4%; all P < 0.001), pancytopenia, higher ESR/anti-dsDNA, and lower C3/C4 . CD4 + CD28 + T-cells declined stepwise from controls (CD4 + CD28: 12.7 ± 3.8%) to (8.1 ± 3.1%) in low-activity SLE patients to (4.6 ± 3.2%) in high-activity SLE patients. On the other hand CD8 + CD28 + T-cells in controls (9.1 ± 3.8%) were then mildly elevated to (11.2 ± 5.5%) in low-activity SLE patients and then declined again to (4.1 ± 2.8%) in high-activity SLE patients (all P < 0.001). These showed strong inverse correlations with the SLEDAI-2 K score ( r = − 0.564 for CD4 + CD28 and r = − 0.685 for CD8 + CD28, all p values < 0.001). They remained independently associated in multivariate regression analysis (B = − 0.83 and − 0.84, respectively; both P < 0.001), even after adjustment for age and disease duration. Conclusions The expression percentages of CD28 on CD4 + and CD8 + T-cells is strongly linked with disease activity and clinical manifestations in SLE patients. So the study indicates that CD28 may serve as a potential biomarker for disease activity in SLE patients.
No takes yet. Share an insight, caveat, or question.
Ebedy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: